Key result
This paper reviews the historical development and clinical controversies surrounding the renin inhibitor aliskiren.
Answers are grounded in this paper and cite their sources.
Requires caution with aliskiren in hypertension; leaves open its guideline role without new randomized data.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ménard et al. (2007) reported a review. Aliskiren was evaluated. This paper reviews the historical development and clinical controversies surrounding the renin inhibitor aliskiren.
Synapse has enriched 10 related papers. Consider them for comparative context: